Argenx Stock - Weekly sector check after recent analyst moves

Argenx stock sits in a strong position within the European biotech cohort as investors digest recent analyst target updates and look ahead to the next earnings date. A weekly sector view highlights how the rare-disease specialist compares to key biotech peers.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 18:00 UTC. Details in the imprint.

Argenx (NL0010832176) is drawing steady attention from biotech investors this week as the rare-disease specialist holds its place among Europe’s higher-valued drug developers. Recent weeks have seen several brokers reiterate positive views on the stock, according to market data.

How Argenx sits in biotech this week

Argenx is widely followed as a mid-to-large-cap biotech name focused on autoimmune diseases, and it often trades alongside European and US biotech benchmarks such as the STOXX Europe 600 Health Care and the Nasdaq biotech cohort.

Market data from European trading platforms show Argenx listed with ISIN NL0010832176 and WKN A11602, underlining its European base even though many brokers reference the US ticker ARGX in their research.

Weekly review and peer comparison

This week, sector watchers again compared Argenx with high-profile peers including Genmab, MorphoSys’s legacy oncology assets under new ownership, and US-listed rare-disease players, highlighting similar exposure to high-cost, specialty therapies.

Analyst commentary compiled by financial portals points out that several houses, including H.C. Wainwright, have recently reiterated Buy ratings on Argenx shares with triple-digit price targets in US dollars, underlining a broadly constructive stance on the company’s pipeline.

The product behind the stock

Argenx generates its current revenue base mainly from its antibody therapy efgartigimod, marketed as Vyvgart for certain autoimmune indications, while also advancing a broader pipeline of antibody-based drug candidates targeting rare immune-mediated diseases.

Where the stock trades today

The shares of Argenx (NL0010832176) trade on Euronext Brussels at EUR 763.80 as of 06/19/2026, 17:30 CET.

Key facts on Argenx stock

• Company: argenx SE
• ISIN: NL0010832176
• WKN: A11602
• Ticker: ARGX
• Venue: Euronext Brussels
• Price (as of 06/19/2026, 17:30 CET): 763.80 EUR
• Market cap: 44,000,000,000 EUR (as of 06/19/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: EURO STOXX 50
• Next earnings date: 07/23/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.